AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32912462 — intervention group
Group type: COMPARATOR
Intervention: LVEDP-guided hydration (normal saline infusion rate adjusted according to LVEDP)
Number of subjects: 702
Study 32912462 — intervention group
Group type: EXPERIMENTAL
Intervention: UFR-guided hydration
Number of subjects: 702
Study 32912462 — intervention group
Group type: COMPARATOR
Intervention: LVEDP-guided hydration
Number of subjects: 702
Study 35436920 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-recumbent vibration exercise
Number of subjects: 32
Study 35436920 — intervention group
Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 32
Study 35421821 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous levobupivacaine/ropivacaine
Number of subjects: 24
Study 35421821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32392833 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented-reality-based muscle reduction prevention exercise program (30-min program, 5 times a week for 12 weeks)
Number of subjects: 27
Study 32392833 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented-reality-based muscle reduction prevention exercise program
Number of subjects: 27
Study 35589024 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong and Tai Chi Easy (QTC)
Number of subjects: 50
Study 35589024 — intervention group
Group type: EXPERIMENTAL
Intervention: QTC plus HRV biofeedback
Number of subjects: 50
Study 33187696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol stove (n = 113)
Number of subjects: 223
Study 33187696 — intervention group
Group type: COMPARATOR
Intervention: Firewood/Kerosene (n = 110)
Number of subjects: 223
Study 32228328 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum attenuation set to 130 HU
Number of subjects: 40
Study 32228328 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum attenuation set to 150 HU
Number of subjects: 40
Study 32228328 — intervention group
Group type: COMPARATOR
Intervention: Minimum attenuation change from 130 HU to 150 HU
Number of subjects: 40
Study 33462482 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO histo-blood groups and FUT2 secretor status
Number of subjects: 8956
Study 33462482 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbes
Number of subjects: 8956
Study 33028560 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint visits with adult and paediatric gastroenterologist (4 visits between ages 17 and 18)
Number of subjects: 160
Study 33028560 — intervention group
Group type: COMPARATOR
Intervention: Usual care (only meeting with paediatric gastroenterologist)
Number of subjects: 160
Study 33028560 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint visits
Number of subjects: 160
Study 35147535 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care Pathway including a sequential pharmacological algorithm and structured behavioral interventions
Number of subjects: 0
Study 35147535 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 0
Study 33105345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiation therapy (RT)
Number of subjects: 180
Study 33105345 — intervention group
Group type: COMPARATOR
Intervention: No pelvic radiation therapy (no-RT)
Number of subjects: 180
Study 33105345 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of mesh complications between RT and no-RT groups
Number of subjects: 180
Study 32870162 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of MI and CBT components, specifically the listing of high-risk situations.
Number of subjects: 503
Study 32870162 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of change talk and number of listed strategies to deal with high-risk situations.
Number of subjects: 503
Study 34148714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice/extract
Number of subjects: 120
Study 34148714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthing of visibly dirty fomites
Number of subjects: 494
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthing of visibly dirty objects
Number of subjects: 494
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthing of dirt
Number of subjects: 494
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthing of feces
Number of subjects: 494
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of mouthing visibly dirty fomites
Number of subjects: 494
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of mouthing objects
Number of subjects: 494
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of mouthing soil
Number of subjects: 494
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of mouthing feces
Number of subjects: 494
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthing of visibly dirty fomites among children 12-18 months
Number of subjects: 494
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthing of visibly dirty fomites among children 12-18 months (observed)
Number of subjects: 494
Study 32406964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthing feces and odds of diarrhea
Number of subjects: 494
Study 35524339 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1981
Number of subjects: 81
Study 35524339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 32818949 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) intravenous infusion
Number of subjects: 67
Study 32818949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 35545106 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-RADS v2.1
Number of subjects: 239
Study 35545106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PI-RADS v2.1 scores 1 and 2
Number of subjects: 239
Study 32660261 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular exercise with cognitive functional therapy
Number of subjects: 72
Study 32660261 — intervention group
Group type: COMPARATOR
Intervention: Scapular exercise alone
Number of subjects: 72
Study 36274193 — intervention group
Group type: EXPERIMENTAL
Intervention: Boolean2.0 criteria
Number of subjects: 2048
Study 36274193 — intervention group
Group type: COMPARATOR
Intervention: Boolean1.0 criteria
Number of subjects: 2048
Study 36274193 — intervention group
Group type: EXPERIMENTAL
Intervention: SDAI remission criteria
Number of subjects: 2048
Study 36274193 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI remission criteria
Number of subjects: 2048
Study 33729393 — intervention group
Group type: EXPERIMENTAL
Intervention: Footwear designed to enhance energy return (TPU)
Number of subjects: 11
Study 33729393 — intervention group
Group type: COMPARATOR
Intervention: Minimalist shoes
Number of subjects: 11
Study 35861974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal rt‐PA injection before vitrectomy
Number of subjects: 38
Study 35861974 — intervention group
Group type: COMPARATOR
Intervention: No injection (control group)
Number of subjects: 38
Study 36127726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100 µg/25 µg once daily for 14 days
Number of subjects: 27
Study 36127726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 33513483 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% FOS
Number of subjects: 18
Study 33513483 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% FOS
Number of subjects: 18
Study 33513483 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ng/L TPT + 0.4% FOS
Number of subjects: 18
Study 33513483 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ng/L TPT + 0.8% FOS
Number of subjects: 18
Study 33513483 — intervention group
Group type: COMPARATOR
Intervention: 10 ng/L TPT
Number of subjects: 18
Study 33513483 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 32970035 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-worn alarm (n = 41)
Number of subjects: 86
Study 32970035 — intervention group
Group type: COMPARATOR
Intervention: Bell-and-pad alarm (n = 45)
Number of subjects: 86
Study 34342760 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized palpation of the temporalis muscle with a 2.0-kg stimulus intensity for 10 seconds
Number of subjects: 32
Study 34342760 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized palpation of the temporalis muscle with a 2.0-kg stimulus intensity for 5 seconds
Number of subjects: 32
Study 34342760 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized palpation of the temporalis muscle with a 2.0-kg stimulus intensity for 2 seconds
Number of subjects: 32
Study 34342760 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized palpation of the temporalis muscle with varying durations and intensities
Number of subjects: 32
Study 34108175 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTOPuS intervention
Number of subjects: 426
Study 34415257 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid nasal dressing
Number of subjects: 80
Study 34415257 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 80
Study 33065813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/d
Number of subjects: 209
Study 33065813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 35120269 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ballooning technique
Number of subjects: 340
Study 35120269 — intervention group
Group type: COMPARATOR
Intervention: Jailed wire technique
Number of subjects: 340
Study 33079570 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulants (DOACs)
Number of subjects: 249
Study 34035401 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 1723
Study 34035401 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not treated with colchicine)
Number of subjects: 1723
Study 33860672 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg three-times a day for 5 days
Number of subjects: 28
Study 33860672 — intervention group
Group type: COMPARATOR
Intervention: Control (no midodrine)
Number of subjects: 28
Study 35973473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporopollenin exine capsules (SpECs) containing vitamin D
Number of subjects: 0
Study 35973473 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D alone
Number of subjects: 0
Study 33774956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omega 3 in standard dose along with oral isotretinoin
Number of subjects: 60
Study 33774956 — intervention group
Group type: COMPARATOR
Intervention: Placebo along with oral isotretinoin
Number of subjects: 60
Study 36149730 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional therapy (Group 1)
Number of subjects: 0
Study 36149730 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional therapy and mobile health agent (Group 2)
Number of subjects: 0
Study 36149730 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health agent (Group 3)
Number of subjects: 0
Study 36149730 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 4)
Number of subjects: 0
Study 34039871 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + 99Tc-MDP
Number of subjects: 177
Study 34039871 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 177
Study 34039871 — intervention group
Group type: COMPARATOR
Intervention: 99Tc-MDP
Number of subjects: 177
Study 33430476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (therapy on dry land and aquatic therapy with Ai Chi)
Number of subjects: 45
Study 33430476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ai Chi aquatic therapy
Number of subjects: 45
Study 33430476 — intervention group
Group type: COMPARATOR
Intervention: Dry land therapy (control group)
Number of subjects: 45
Study 35042175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal (IV) PGE2 (2 mg)
Number of subjects: 212
Study 35042175 — intervention group
Group type: COMPARATOR
Intervention: Intracervical (IC) PGE2 (0.5 mg)
Number of subjects: 212
Study 34695832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's bed incline at 45°
Number of subjects: 254
Study 34695832 — intervention group
Group type: COMPARATOR
Intervention: Mother's bed incline at 15°
Number of subjects: 254
Study 35109906 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fusidic acid
Number of subjects: 0
Study 34855609 — intervention group
Group type: EXPERIMENTAL
Intervention: StepMATE app with additional supports for walking (experimental group)
Number of subjects: 96
Study 34855609 — intervention group
Group type: COMPARATOR
Intervention: Basic, pedometer-like version of the StepMATE app (control group)
Number of subjects: 96
Study 34855609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combined)
Number of subjects: 96
Study 35918438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral serratus anterior plane block (SAPB) with 3 mg/kg 0.25% ropivacaine
Number of subjects: 60
Study 35918438 — intervention group
Group type: COMPARATOR
Intervention: Incision infiltration (II) with 3 mg/kg 0.75% ropivacaine
Number of subjects: 60
Study 33978115 — intervention group
Group type: EXPERIMENTAL
Intervention: Octagon FOPNL
Number of subjects: 2400
Study 33978115 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangle FOPNL
Number of subjects: 2400
Study 33978115 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle FOPNL
Number of subjects: 2400
Study 33978115 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic Light FOPNL
Number of subjects: 2400
Study 33978115 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifier FOPNL
Number of subjects: 2400
Study 33978115 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 2400
Study 32648838 — intervention group
Group type: EXPERIMENTAL
Intervention: Music of the child's choice
Number of subjects: 150
Study 32648838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lullaby music
Number of subjects: 150
Study 32648838 — intervention group
Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 150
Study 32648838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic sedation
Number of subjects: 150
Study 35246048 — intervention group
Group type: EXPERIMENTAL
Intervention: NTI (Nociceptive Trigeminal Inhibition) oral device
Number of subjects: 0
Study 35246048 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 0
Study 34081923 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine recipients
Number of subjects: 2046
Study 34081923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine recipients
Number of subjects: 2046
Study 36085130 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to the Qur'an during the postoperative period
Number of subjects: 112
Study 36085130 — intervention group
Group type: COMPARATOR
Intervention: Natural environment audio and Fentanyl for pain relief (Control)
Number of subjects: 112
Study 33452217 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliVue ECG
Number of subjects: 39
Study 33452217 — intervention group
Group type: COMPARATOR
Intervention: Nellcor PO
Number of subjects: 39
Study 33590594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration stimulation during intramuscular injection
Number of subjects: 84
Study 33590594 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular injection without vibration stimulation
Number of subjects: 84
Study 32938208 — intervention group
Group type: EXPERIMENTAL
Intervention: QSAR model using quadratic transfer function
Number of subjects: 0
Study 32938208 — intervention group
Group type: COMPARATOR
Intervention: Other S-shaped and V-shaped transfer functions
Number of subjects: 0
Study 35701109 — intervention group
Group type: EXPERIMENTAL
Intervention: Concussion information (CI)
Number of subjects: 199
Study 35701109 — intervention group
Group type: COMPARATOR
Intervention: Non-concussion information (non-CI)
Number of subjects: 199
Study 34587960 — intervention group
Group type: EXPERIMENTAL
Intervention: Online culturally informed intervention (n=34)
Number of subjects: 72
Study 34587960 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 72
Study 34340675 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intrafascial cysprostatectomy
Number of subjects: 44
Study 34340675 — intervention group
Group type: COMPARATOR
Intervention: Conventional interfascial surgeries
Number of subjects: 44
Study 35725523 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 256 µg/day
Number of subjects: 206
Study 35725523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 33276764 — intervention group
Group type: COMPARATOR
Intervention: Static stretching exercise
Number of subjects: 45
Study 33276764 — intervention group
Group type: COMPARATOR
Intervention: Strengthening exercise in lengthened hamstring position
Number of subjects: 45
Study 33276764 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 33276764 — intervention group
Group type: COMPARATOR
Intervention: Height of patients
Number of subjects: 45
Study 35260042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hype Energy Drink (HED)
Number of subjects: 22
Study 35260042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 35180319 — intervention group
Group type: EXPERIMENTAL
Intervention: Interconnected Systems Framework
Number of subjects: 0
Study 35759521 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-cranking
Number of subjects: 10
Study 35759521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 10
Study 32162213 — intervention group
Group type: EXPERIMENTAL
Intervention: Willpower beliefs (nonlimited vs limited)
Number of subjects: 243
Study 32162213 — intervention group
Group type: EXPERIMENTAL
Intervention: Health demands (OAK severity, BMI, depressive symptoms)
Number of subjects: 243
Study 35909224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency telephone contacts (TEL) for CADG patients
Number of subjects: 240
Study 35909224 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent drinking goal (ADG)
Number of subjects: 240
Study 35909224 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional abstinence drinking goal (CADG)
Number of subjects: 240
Study 35909224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contact)
Number of subjects: 240
Study 34132695 — intervention group
Group type: EXPERIMENTAL
Intervention: Early prehospital tranexamic acid (TXA) administered within 1 hour from time of injury
Number of subjects: 238
Study 34132695 — intervention group
Group type: COMPARATOR
Intervention: Delayed prehospital tranexamic acid (TXA) administered beyond 1 hour from time of injury
Number of subjects: 238
Study 34132695 — intervention group
Group type: EXPERIMENTAL
Intervention: Early prehospital tranexamic acid (TXA)
Number of subjects: 238
Study 32706639 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemohormonal therapy (CHT) with androgen deprivation plus docetaxel (75 mg/m2 every 3 weeks for 6 cycles) and radical prostatectomy (RP)
Number of subjects: 788
Study 32706639 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy (RP) alone
Number of subjects: 788
Study 34977421 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health self-monitoring
Number of subjects: 0
Study 34977421 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined digital health and community health worker support
Number of subjects: 0
Study 34977421 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetes care
Number of subjects: 0
Study 36041750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept 0.3 or 0.7 mg·kg‐1 (placebo-crossed group)
Number of subjects: 106
Study 36041750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept (continued-sotatercept group)
Number of subjects: 106
Study 36041750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial control group)
Number of subjects: 106
Study 36041750 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall safety evaluation
Number of subjects: 106
Study 33436053 — intervention group
Group type: EXPERIMENTAL
Intervention: Jin’s three‐needle acupuncture (JTN) combined with mirror therapy (MT)
Number of subjects: 0
Study 33436053 — intervention group
Group type: COMPARATOR
Intervention: Jin’s three‐needle acupuncture (JTN)
Number of subjects: 0
Study 32337679 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PBM + physiotherapy
Number of subjects: 30
Study 32337679 — intervention group
Group type: COMPARATOR
Intervention: Sham PBM + physiotherapy
Number of subjects: 30
Study 35240478 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 2620
Study 35240478 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal/observational studies
Number of subjects: 2620
Study 35240478 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses/systematic reviews/practice guidelines
Number of subjects: 2620
Study 35240478 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomized controlled trials
Number of subjects: 2620
Study 35240478 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetrics and gynecology journals
Number of subjects: 2620
Study 35240478 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral vascular disease journals
Number of subjects: 2620
Study 35240478 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency medicine journals
Number of subjects: 2620
Study 35240478 — intervention group
Group type: COMPARATOR
Intervention: Surgery journals
Number of subjects: 2620
Study 35240478 — intervention group
Group type: COMPARATOR
Intervention: Pediatrics journals
Number of subjects: 2620
Study 35240478 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary journals
Number of subjects: 2620
Study 33962499 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal supplement (Combi-5) taken along with vitamin C and Zinc supplements
Number of subjects: 1
Study 33962499 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 1
Study 33310864 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 165
Study 33310864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165